Clinical effects and biomarkers of biological agents on asthma

Clinical investigation on the effects of biological agents on asthma and search for biological markers - Clinical effects and biomarkers of biological agents on asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1031190033

Enrollment

Registered

2019-05-28

Start date

2019-07-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma asthma

Interventions

none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Asthma patients diagnosed based on Japanese Asthma Prevention and Management Guideline 2018 who are older than 12 years old 2) Either anti-IgE antibody (Zorea), anti-IL-5 antibody (Nucala), or anti-IL-5 receptor antibody (Facenra) is going to be administered. 3) Written informed consent from the patients or the legal gardian is obtained.

Exclusion criteria

Exclusion criteria: 1) Those patients who can not be taken blood sample 2) Those patients who were judged not suitable for the entry to this investigation be the responsible doctor

Design outcomes

Primary

Measure	Time frame
Asthma control questionnaire (ACQ)	—

Secondary

Measure	Time frame
Respiratory function test, SABA usage, acute exacerbation, serum biomarker (IL-5, etc)	—

Contacts

Public ContactMIYAKO YAMAGUCHI

National Hospital Organization, Sagamihara National Hospital

yamaguchi.miyako.eg@mail.hosp.go.jp+81-42-742-8311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026